Biased Ligands. Better Drugs.

TRV250 preclinical studies

TRV250: a novel biased ligand at the delta receptor for the potential treatment of migraine

Aimee L. Crombie, Joseph Arezzo, Conrad L. Cowan, Scott M. DeWire, William Gowen-MacDonald, Michael J. Hawkins, Emily M. Jutkiewicz, Michael S. Kramer, Michael Koblish, Michael W. Lark, Guodong Liu, Tamara Miskowski, Lisa Nguyen, Philip M. Pitis, Amynah Pradhan, David H. Rominger, Erica S. Schwartz, Dennis S. Yamashita, Jonathan D. Violin.

View PDF

Copyright © Trevena, Inc.